REATA PHARMACEUTICALS INC-A (RETA) Forecast, Price Target & Analyst Ratings

NASDAQ:RETA • US75615P1030

Current stock price

172.36 USD
+0.04 (+0.02%)
At close:
172.4 USD
+0.04 (+0.02%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for REATA PHARMACEUTICALS INC-A (RETA).

Forecast Snapshot

Consensus Price Target

Price Target
$175.90
+ 2.05% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Nov 6, 2023
Period
Q3 / 2023
EPS Estimate
-$2.13
Revenue Estimate
29.575M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
53.33%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$175.90
Upside
+ 2.05%
From current price of $172.36 to mean target of $175.90, Based on 15 analyst forecasts
Low
$173.72
Median
$175.95
High
$181.65

Price Target Revisions

1 Month
0.00%
3 Months
53.21%

Price Target Summary

15 Wall Street analysts provided a forecast for the next 12 months for RETA. The average price target is 175.9 USD. This implies a price increase of 2.05% is expected in the next year compared to the current price of 172.36.
The average price target has been revised upward by 53.21% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

RETA Current Analyst RatingRETA Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

RETA Historical Analyst RatingsRETA Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15

Analyst Ratings Consensus

ChartMill Buy Consensus
53.33%
RETA was analyzed by 15 analysts. The buy percentage consensus is at 53. So analysts seem to be rather neutral about RETA.
In the last month the buy percentage fell by 17 points. So the trust of analysts is decreasing.
RETA was analyzed by 15 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2023-08-15Cantor FitzgeraldReiterate Neutral -> Neutral
2023-08-01BarclaysDowngrade Overweight -> Equal-Weight
2023-08-01CitigroupDowngrade Buy -> Neutral
2023-07-31Ladenburg ThalmannDowngrade Buy -> Neutral
2023-07-31BairdMaintains Outperform -> Outperform
2023-07-31JefferiesDowngrade Buy -> Hold
2023-07-28StifelDowngrade Buy -> Hold
2023-07-24Cantor FitzgeraldMaintains Overweight -> Overweight
2023-07-06TD CowenInitiate Outperform
2023-06-29Ladenburg ThalmannMaintains Buy -> Buy
2023-06-28Cantor FitzgeraldReiterate Overweight -> Overweight
2023-06-28BarclaysMaintains Overweight -> Overweight
2023-06-12SVB LeerinkUpgrade Market Perform -> Outperform
2023-05-11BarclaysMaintains Overweight -> Overweight
2023-04-13StifelMaintains Buy
2023-03-27Cantor FitzgeraldMaintains Overweight
2023-03-01Cantor FitzgeraldMaintains Overweight
2023-03-01BarclaysMaintains Overweight
2023-03-01BairdMaintains Neutral
2023-03-01Goldman SachsMaintains Buy
2023-03-01CitigroupMaintains Buy
2023-02-24Goldman SachsMaintains Buy
2022-11-28Goldman SachsMaintains Buy
2022-11-09BarclaysMaintains Overweight
2022-11-09Goldman SachsMaintains Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Nov 6, 2023
Period
Q3 / 2023
EPS Estimate
-$2.13
Revenue Estimate
29.575M
Revenue Q2Q
5,376.85%
EPS Q2Q
1.24%
Number of Analysts
12

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
51.67%
EPS (1 Month)
0.00%
EPS (3 Months)
13.57%

Next Earnings Summary

RETA is expected to report earnings on 11/6/2023. The consensus EPS estimate for the next earnings is -2.13 USD and the consensus revenue estimate is 29.57M USD.
The next earnings revenue estimate has been revised upward by 51.67% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2023 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
RETA revenue by date.RETA revenue by date.
9.02M
-65.99%		11.49M
27.38%		2.216M
-80.71%		92.691M
4,082.81%		405.2M
337.15%		668.5M
64.98%		942.78M
41.03%		1.411B
49.66%		1.736B
23.03%		1.942B
11.87%		2.085B
7.36%
EBITDA
YoY % growth
RETA ebitda by date.RETA ebitda by date.
-225.19M
20.79%		-243.505M
-8.13%		-276.904M
-13.72%		-312.868M
-12.99%		-45.257M
85.53%		109.47M
341.88%		128.51M
17.39%		395.72M
207.93%		665.17M
68.09%		834.08M
25.39%		1.02B
22.29%
EBIT
YoY % growth
RETA ebit by date.RETA ebit by date.
-226.33M
20.65%		-244.708M
-8.12%		-278.034M
-13.62%		-369.477M
-32.89%		-89.684M
75.73%		206.32M
330.05%		531.42M
157.57%		972.47M
82.99%		1.218B
25.25%		1.383B
13.55%		1.448B
4.70%
Operating Margin
RETA operating margin by date.RETA operating margin by date.
-2,509.20%-2,129.75%-12,546.66%-398.61%-22.13%30.86%56.37%68.92%70.16%71.22%69.45%
EPS
YoY % growth
RETA eps by date.RETA eps by date.
-6.98
-38.77%		-8.18
-17.19%		-8.54
-4.40%		-6.81
20.24%		-4.48
34.18%		3.13
169.81%		3.08
-1.59%		8.29
169.21%		13.40
61.62%		16.39
22.30%		19.56
19.35%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q3 / 23 Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-2.13
1.24%		-1.88
19.52%		-2.00
36.17%		-1.31
-128.19%		-0.74
65.33%		-0.17
91.02%
Revenue
Q2Q % growth		29.575M
5,376.85%		41.79M52.483M
26,814.36%		92.943M
308.61%		126.11M
326.41%		160.73M
284.61%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-81.578M
-15.74%		-82.705M
-4.00%		-75.629M
31.53%		-48.528M
40.24%		-25.33M
68.95%		-2.262M
97.26%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

RETA Yearly Revenue VS EstimatesRETA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B
RETA Yearly EPS VS EstimatesRETA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 10 15

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
33.26%
EPS Next 5 Year
24.33%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
529.02%
Revenue Next 5 Year
250.01%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
33.80%
EBIT Next 5 Year
27.95%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

REATA PHARMACEUTICALS INC-A / RETA Forecast FAQ

Can you provide the average price target for REATA PHARMACEUTICALS INC-A stock?

15 analysts have analysed RETA and the average price target is 175.9 USD. This implies a price increase of 2.05% is expected in the next year compared to the current price of 172.36.

Can you provide the upcoming earnings date for REATA PHARMACEUTICALS INC-A?

REATA PHARMACEUTICALS INC-A (RETA) will report earnings on 2023-11-06, before the market open.

What are the consensus estimates for REATA PHARMACEUTICALS INC-A (RETA) next earnings?

The consensus EPS estimate for the next earnings of REATA PHARMACEUTICALS INC-A (RETA) is -2.13 USD and the consensus revenue estimate is 29.57M USD.

How many analysts have analysed REATA PHARMACEUTICALS INC-A (RETA)?

The number of analysts covering REATA PHARMACEUTICALS INC-A (RETA) is 15.